Biomea Fusion, Inc. entered into an underwriting agreement to issue and sell 5,000,000 shares of common stock at a public offering price of $30.00 per share, with an option for the underwriters to purchase an additional 750,000 shares. The net proceeds of approximately $161.6 million will be used for clinical development, exploration of potential clinical utility, IND-enabling studies, product development, and general corporate purposes.